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Abstract
Background: b2GPI is a major antigen for autoantibodies associated with antiphospholipid syndrome (APS), an
autoimmune disease characterized by thrombosis and recurrent pregnancy loss. Only the dimeric form of b2GPI generated
by anti-b2GPI antibodies is pathologically important, in contrast to monomeric b2GPI which is abundant in plasma.
Principal Findings: We created a dimeric inhibitor, A1-A1, to selectively target b2GPI in b2GPI/antibody complexes. To make
this inhibitor, we isolated the first ligand-binding module from ApoER2 (A1) and connected two A1 modules with a flexible
linker. A1-A1 interferes with two pathologically important interactions in APS, the binding of b2GPI/antibody complexes
with anionic phospholipids and ApoER2. We compared the efficiency of A1-A1 to monomeric A1 for inhibition of the
binding of b2GPI/antibody complexes to anionic phospholipids. We tested the inhibition of b2GPI present in human serum,
b2GPI purified from human plasma and the individual domain V of b2GPI. We demonstrated that when b2GPI/antibody
complexes are formed, A1-A1 is much more effective than A1 in inhibition of the binding of b2GPI to cardiolipin, regardless
of the source of b2GPI. Similarly, A1-A1 strongly inhibits the binding of dimerized domain V of b2GPI to cardiolipin
compared to the monomeric A1 inhibitor. In the absence of anti-b2GPI antibodies, both A1-A1 and A1 only weakly inhibit
the binding of pathologically inactive monomeric b2GPI to cardiolipin.
Conclusions: Our results suggest that the approach of using a dimeric inhibitor to block b2GPI in the pathological
multivalent b2GPI/antibody complexes holds significant promise. The novel inhibitor A1-A1 may be a starting point in the
development of an effective therapeutic for antiphospholipid syndrome.
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Introduction
Beta2-glycoprotein I (b2GPI) is the major target for autoim-
mune antibodies associated with antiphospholipid syndrome
(APS), an autoimmune disease characterized clinically by
thrombosis and recurrent pregnancy loss [1,2,3,4]. Presently,
APS patients with thrombotic complications who have high titers
of antibodies are treated chronically with anticoagulants [5,6,7].
However, even continuous anticoagulation may not prevent
recurrent thrombosis [5], emphasizing the need for a more
effective antithrombotic therapy based on the thrombogenic
mechanisms specific to APS.
b2GPI consists of five domains [8,9]. Flexible linkers between
domains permit b2GPI to adopt different overall shapes such as a
fishhook-like shape seen in the crystal structure [8,9], an S-shape
observed by small angle x-ray scattering for b2GPI in solution [10]
and a circular shape detected by electron microscopy [11]. The
circular shape in which domain I is adjacent to domain V is the
predominant conformation of b2GPI in normal human plasma
[11]. Circular b2GPI can be converted to an extended form by
altering pH and salt concentrations, binding to a high-affinity
antibody directed to domain I or by the binding to cardiolipin [11].
b2GPI, which is abundant in plasma (about 170 mg/ml or 4 mM)
[12], acquires its prothrombotic properties only in the presence of
anti-b2GPI antibodies. Antibodies of the IgG isotype have the
highest correlation with the clinical manifestations of APS
compared to other identified antibodies [13,14]. Although anti-
b2GPI antibodies in APS patients are highly heterogeneous in
respect to their affinity for b2GPI and the location of their binding
epitopes, autoantibodies against domain I are the most common
and better correlate with thrombosis [15,16]. The presence of anti-
b2GPI antibodies causes cellular activation both in vitro and in vivo
[17,18,19]. Toll-like receptors, annexin A2, ApoE receptor
(ApoER2), platelet receptor GPIb and anionic phospholipids
exposed on cellular surfaces of activated cells are suggested to be
pathologically important in APS [18,19,20,21,22,23,24,25,-
26,27,28,29]. The binding sites for anionic phospholipids
[30,31,32,33], lipoprotein receptors (including ApoER2) [34] and
GPIb [21] are in domain V of b2GPI (b2GPI-DV).
In the present studies, we are suggesting a novel approach to
interference with anti-b2GPI-dependent thrombosis in APS. To
prevent the b2GPI/antibody complexes from the binding to
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15345receptors, we designed an inhibitor that a) targets b2GPI and b)
binds tightly to b2GPI/antibody complexes expressing the dimeric
b2GPI but binds weakly to b2GPI monomers. These requirements
have the following rationale: First, complete b2GPI deficiency in
humans, although rare, does not lead to apparent health problems
[35,36,37], therefore the inhibitor that targets b2GPI will not
disrupt normal biological processes. Second, b2GPI/anti-b2GPI
antibody complexes expressing dimeric b2GPI but not monomeric
b2GPI are pathologically important [28,38], therefore the
inhibitor should bind preferentially to b2GPI/anti-b2GPI com-
plex compared to b2GPI monomers. Anti-b2GPI antibodies
constitute less than 3% of total IgG in patients with antiphospho-
lipid syndrome and have weak affinity for b2GPI [39,40,41]. In
contrast to b2GPI monomers which are abundant in plasma,
b2GPI/anti-b2GPI complexes are present at low concentration.
In this study, we are focusing on the inhibition of the binding of
b2GPI/anti-b2GPI antibody complexes to ApoER2 and to
anionic phospholipids. ApoER2, like other members of the family
of lipoprotein receptors, binds b2GPI via structurally homologous
ligand-binding type A (LA) modules and the first LA module of
ApoER2 is the most important for the binding [42,43,44,45].
Recently, we have shown that different LA modules bind to the
same site on b2GPI and that b2GPI can not simultaneously bind
an LA module and a cardiolipin-coated surface [46]. Therefore,
an LA module bound to b2GPI has dual action: it inhibits both the
binding of b2GPI to lipoprotein receptors and anionic phospho-
lipids expressed on cells.
We created a dimeric inhibitor, A1-A1. To make this inhibitor,
we isolated the first LA module from ApoER2 (A1) and connected
two A1 modules with a flexible linker. In the present studies, we
compared a monomeric A1 with A1-A1 on interfering with the
binding of b2GPI/anti-b2GPI antibody complexes to anionic
phospholipids. We tested the inhibition of b2GPI present in
human serum, b2GPI purified from human plasma and domain V
of b2GPI. b2GPI in serum is the circular form of b2GPI [11] and
the individual domain V represents b2GPI in the extended
conformation. We demonstrated that when b2GPI/antibody
complexes are formed, A1-A1 is more effective than A1 in
inhibition of b2GPI binding to cardiolipin, regardless of the source
of b2GPI. Similarly, A1-A1 strongly inhibits the binding of
dimerized domain V of b2GPI to cardiolipin compared to the
monomeric A1 inhibitor. Moreover, A1-A1 preferentially binds
b2GPI/anti-b2GPI antibody complexes and binds only weakly to
monomeric b2GPI. The novel inhibitor A1-A1 may be a starting
point in the development of an effective drug for prevention and
treatment of b2GPI-dependent thrombosis in antiphospholipid
syndrome.
Results
Design of a dimeric inhibitor
Recently, we have shown that the first LA module from
ApoER2 (A1) binds domain V of b2GPI with 1 mM affinity [46].
In order to target a multivalent b2GPI formed by anti-b2GPI
antibodies, we made a dimeric inhibitor consisting of two A1
modules covalently connected by a linker. To allow largely
unrestricted relative motion of two A1 modules in the A1-A1
molecule, we used a flexible linker Gly-Ser-Ser-Gly to connect A1
modules. In extended conformation, this four-residue linker is
capable of separating the A1 modules in A1-A1 by up to 15 A ˚.W e
expressed and purified A1-A1 using the same procedure that we
have previously used for the expression and purification of other
LA modules including A1. Our previous analysis of different
recombinantly expressed LA modules by solution NMR spectros-
copy and crystallography demonstrated that the purified LA
modules are properly folded, their structures are identical to the
structures of these modules in full-length receptors and, in the
presence of calcium, recombinant LA modules bind their ligands
b2GPI, b2GPI-DV, RAP and ApoE [46,47,48,49]. Because
calcium is essential for the function of LA modules and the
formation of native disulfide bonds [50], we analyzed the folding
of the dimeric molecule, A1-A1, in the presence and absence of
calcium. We compared the oxidative refolding of A1-A1 to the
refolding of A1, which yields a functional A1 module. The same
quantities of the recombinant proteins were dialyzed in redox
buffer containing either calcium or EDTA. After 36 hours
(samples with A1) or 72 hours (samples with A1-A1) of refolding,
the proteins were acidified with 0.1% TFA to stop the disulfide
exchange and analyzed by a reversed-phase HPLC on an
analytical C18 column. The A1 module contains six cysteine
residues forming three disulfide bonds. In the presence of calcium,
both A1 and A1-A1 converged to unique disulfide-bonded species
out of many possibilities providing evidence that the presence of
calcium guided formation of native disulfide bonds (Figure 1A,B).
For comparison, refolding of A1 and A1-A1 in the presence of
EDTA yielded a distribution of multiple disulfide-bonded isomers.
Comparison of the dimeric inhibitor A1-A1 with
monomeric A1. Inhibition of the binding of b2GPI to
cardiolipin
Anti-b2GPI antibodies create multivalent b2GPI/anti-b2GPI
complexes that have pathological properties compared to
pathologically inactive b2GPI monomers, which are normally
present in plasma. The binding of b2GPI to anionic phospholipids
in the presence of anti-b2GPI antibodies is one of the pathological
mechanisms leading to thrombosis and pregnancy losses in
antiphospholipid syndrome. We compared the dimeric inhibitor,
A1-A1, to monomeric A1 on the inhibition of the binding of
b2GPI/anti-b2GPI antibody complexes to cardiolipin coated on a
plate. First, we used pooled normal human serum as a source of
b2GPI. The majority of the b2GPI molecules in serum is in the
circular form [11]. To select the appropriate concentration of
b2GPI for the inhibition studies, we measured the binding curves
(Figure 2A). To create b2GPI/anti-b2GPI complexes, anti-b2GPI
antibodies at constant concentration were added to b2GPI before
the samples were applied to cardiolipin. The presence of anti-
b2GPI antibodies significantly enhanced the binding of b2GPI to
cardiolipin reaching the half-maximal binding at 0.02860.004%
and 0.4060.05% of serum in the presence and in the absence of
anti-b2GPI antibodies, respectively. We then compared the
efficiency of A1-A1 and A1 for the inhibition of the binding of
b2GPI in serum to cardiolipin in the presence of anti-b2GPI
antibodies (Figure 2B). 0.04% of human serum, which is in the
linear region of the binding curve, was incubated on a cardiolipin-
coated surface in the presence of anti-b2GPI antibodies and the
inhibitors. In the presence of anti-b2GPI antibodies, the dimeric
molecule, A1-A1, inhibited the binding to cardiolipin of b2GPI in
serum much stronger than monomeric A1. The half-maximal
inhibition in the presence of anti-b2GPI antibodies was achieved
at 1062 mM of A1-A1 and 218621 mM of A1. Also, we measured
how A1-A1 and A1 inhibited the binding of b2GPI in serum in the
absence of anti-b2GPI antibodies (Figure 3). A 1% solution of
human serum was titrated with A1-A1 or A1. b2GPI bound to
cardiolipin was subsequently detected with anti-b2GPI antibodies.
In the absence of anti-b2GPI antibodies, both A1-A1 and A1 were
equally ineffective in inhibition of b2GPI. The concentration of
the inhibitors at 50% inhibition of b2GPI was 189634 mM for
A1-A1 and 176637 mM for A1. In sum, the efficiency of A1-A1 to
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significantly stronger in the presence of anti-b2GPI antibody than
in the absence of antibodies. The inhibition efficiency of the
monomeric A1 was practically the same and weak regardless of the
presence or absence of anti-b2GPI antibodies. A1-A1 was more
effective than A1 in inhibition of b2GPI in serum in the presence
of anti-b2GPI antibodies.
Next, we analyzed how A1-A1 and A1 inhibit the binding of
purified b2GPI to cardiolipin. Closed and extended conformations
of b2GPI can be interconverted by altering of pH and
concentrations of NaCl in the buffer [11], suggesting that the
conformation of purified b2GPI may depend on the purification
procedure. We used b2GPI purified from human plasma available
from Haematologic Technologies, Inc. and analyzed the binding
and inhibition of the binding of purified b2GPI by A1-A1 and A1
in the presence and in the absence of anti-b2GPI antibodies. The
half-maximal binding was achieved at 2.460.4 nM and 4364n M
of the purified b2GPI in the presence and in the absence of anti-
b2GPI antibodies, respectively (Figure 4A). We incubated 10 nM
of b2GPI with various concentrations of the dimeric, A1-A1, and
monomeric, A1, inhibitors in the presence of anti-b2GPI
antibodies. Similarly to what we observed for b2GPI in serum,
A1-A1 was more effective in inhibition of the binding of b2GPI to
cardiolipin in the presence of anti-b2GPI antibodies. The fit of the
titration data to the one-site inhibition model resulted in
2663 mM of A1-A1 and 191634 mM of A1 at half-maximal
inhibition of purified b2GPI in the presence of anti-b2GPI
antibodies (Figure 4B). In a separate experiment, we measured the
inhibition of b2GPI in the presence of antibodies and compared
the measured values to values predicted by the fit of the titration
data (Figure 4C). The measured values were close to those
expected from the fit, additionally confirming that in the presence
of anti-b2GPI antibodies a much lower concentration of A1-A1
was required to inhibit 50% of the binding of purified b2GPI to
cardiolipin compared to A1. In the absence of anti-b2GPI
antibodies, both A1-A1 and A1 only weakly inhibited the binding
of the purified b2GPI to cardiolipin (Figure 5). Similarly to what
we observed for b2GPI in serum, the binding of purified b2GPI to
cardiolipin in the presence of anti-b2GPI antibodies was inhibited
more strongly by the dimeric inhibitor A1-A1 than by A1. Both,
A1-A1 and A1, were ineffective in the inhibition of b2GPI in the
absence of anti-b2GPI antibodies.
Crystal structure of the isolated domain V of b2GPI
(b2GPI-DV)
b2GPI binds anionic phospholipids and the A1 modules by its
domain V [30,31,33,34,46]. In the crystal structures of a full-
length b2GPI in the extended conformation [8,9], domain V
forms essentially no contacts with the adjacent domain. There are
no glycosylation sites in b2GPI that could affect function of
domain V indicating that the individual domain V (b2GPI-DV)
dissected from the full-length b2GPI will function as domain V in
the extended form of b2GPI. We solved the crystal structure of the
isolated domain V to 1.9 A ˚ resolution (Table 1). As illustrated by
Figure 6, the backbone conformation of b2GPI-DV is nearly
identical to the structure of this domain in the full-length b2GPI.
The largest difference between the structures is localized to a C-
terminal loop. Experimental data strongly suggests that this loop is
flexible in the native protein. For example, the residues from 311
to 317 comprising this loop are not defined in one of the crystal
structures of the full-length b2GPI (PDB ID 1QUB) [8] and have
large values of B-factors in the other (PDB ID 1C1Z) [9]. Also, the
residues in the loop are either weak or missing from the NMR
spectrum of b2GPI-DV in solution reflecting its internal flexibility
[46]. The structural similarity between b2GPI-DV and domain V
in the full-length b2GPI provides convincing evidence that the
isolated recombinant b2GPI-DV mimics domain V in the
extended form of b2GPI.
Comparison of the dimeric inhibitor A1-A1 with
monomeric A1. Inhibition of the binding of the isolated
domain V of b2GPI (b2GPI-DV) to cardiolipin in the
presence of the dimerization antibodies
To analyze how A1-A1 and A1 inhibit the binding of the
extended form of b2GPI to cardiolipin, we used purified domain V
of b2GPI (b2GPI-DV). We introduced a peptide tag at the N-
terminus of b2GPI-DV and used an antibody directed to the tag to
Figure 1. HPLC chromatograms of products formed by oxidative refolding of A1 (A) and A1-A1 (B). The proteins were dialyzed in redox
buffer in the presence of calcium or EDTA and eluted with a linear gradient of 0.1% per minute of acetonitrile containing 0.1% TFA starting at 15
minutes from 21% of acetonitrile/TFA (for A1) or 26% of acetonitrile/TFA (for A1-A1).
doi:10.1371/journal.pone.0015345.g001
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demonstrated that the A1 module binds to the C-terminal part of
b2GPI-DV [46] and, therefore, the N-terminal peptide tag on
b2GPI-DV and the bound anti-tag antibody will not interfere with
the binding of the A1 modules to b2GPI-DV.
As in the case of the full-length b2GPI, the presence of divalent
b2GPI-DV/antibody complexes increased the attachment of
b2GPI-DV to cardiolipin (Figure 7A). The fit of the binding data
to a one-site model resulted in 1961n M o f b2GPI-DV and
112621 nM of b2GPI-DV in the presence and in the absence of
anti-tag antibodies. When 30 nM of b2GPI-DV in the presence of
anti-tag antibody was incubated with the inhibitors, the half-
maximal inhibition was reached at 1262 mM of A1-A1 and
204633 mM of A1 (Figure 7B). As we observed for the inhibition
of the binding of b2GPI in human serum and purified b2GPI to
cardiolipin-coated surfaces, the isolated domain V was inhibited
much stronger by the dimeric inhibitor A1-A1 compared to
monomeric A1 in the presence of dimeric b2GPI-DV/anti-tag
antibody complexes.
Comparison of b2GPI in human serum with the isolated
domain V of b2GPI (b2GPI-DV). Inhibition of the binding
to cardiolipin by a monomeric A1 in the absence of
antibodies
We investigated if the binding of two forms of b2GPI, circular
and extended, to cardiolipin is inhibited similarly by A1. We
analyzed the inhibition of the monomeric molecules, b2GPI in
serum and the isolated domain V, by monomeric A1. The
majority of b2GPI in normal human serum is in a circular
conformation [11]. The isolated domain V mimics this domain in
the extended form of b2GPI. The same concentration of A1 was
required to inhibit 50% of the binding of b2GPI in human serum
and the individual domain V of b2GPI (Figure 8). The
concentration of A1 at half-maximal inhibition was 176637 mM
for b2GPI in serum and 188644 mM for domain V. This
observation demonstrates that A1 binds circular and extended
b2GPI with the same affinity suggesting that the binding site for
A1 is not obscured in the circular form of b2GPI.
Stability of the A1-A1 inhibitor in human serum at 37uC
To evaluate the susceptibility of the A1-A1 inhibitor to
degradation by serum proteases, we incubated A1-A1 in serum
at 37uC. Degradation of A1-A1 was monitored by the reversed-
phase HPLC by comparing the peak corresponding to the intact
A1-A1 on chromatograms collected at different time intervals. The
amount of A1-A1 that remained in serum was calculated from the
area under the eluted peak. More than 35% of A1-A1 remained in
serum after 15 days of incubation at 37uC, indicating that A1-A1
has a favorable stability in serum (Figure 9).
Discussion
The work reported here examines the effectiveness of a novel
dimeric inhibitor A1-A1 to interfere with the binding of
pathological b2GPI/anti-b2GPI antibody complexes to anionic
phospholipids compared to monomeric A1. The dimeric inhibitor,
A1-A1, consists of two ligand-binding A1 modules from ApoER2
Figure 3. Inhibition of the binding of b2GPI in human serum to
cardiolipin in the absence of anti-b2GPI antibodies. Inhibition
curves measured for the dimeric inhibitor A1-A1 (circles) and
monomeric inhibitor A1 (triangles). On the plot, the data points at
50 mM and 100 mM of A1-A1 partially overlap with the corresponding
data points of A1. To facilitate comparison, the measured OD405 values
and the binding curves were normalized to the maximum binding
obtained from the fit of the raw data to a one-site inhibition model.
doi:10.1371/journal.pone.0015345.g003
Figure 2. Binding and inhibition of the binding of b2GPI in
normal human serum to cardiolipin. A) The binding of b2GPI in
serum to cardiolipin-coated surface in the absence (triangles) and in the
presence (circles) of anti-b2GPI antibodies. B) Inhibition of the binding
of b2GPI in human serum to cardiolipin in the presence of anti-b2GPI
antibodies by the dimeric inhibitor A1-A1 (circles) and monomeric
inhibitor A1 (triangles). Fit to one-site binding and inhibition models
was performed on the raw data. To facilitate comparison, the measured
OD405 values and the binding curves were normalized to the maximum
binding obtained from the fit.
doi:10.1371/journal.pone.0015345.g002
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of A1-A1 by reverse-phased chromatography confirmed that it is
correctly folded in a calcium-dependent manner. Recently, we
determined that the bound A1 module prevents the association of
b2GPI with anionic phospholipids [46]. Present studies confirmed
our previous observations suggesting that the dimeric A1 inhibitor
interferes with two pathologically important interactions: the
binding of b2GPI/antibody complexes to anionic phospholipids
expressed on activated cells and to ApoER2, a lipoprotein receptor
on platelets [29,51].
Normally, b2GPI circulates in the blood plasma as a monomer.
Anti-b2GPI antibodies in patients with antiphospholipid syndrome
create multivalent b2GPI complexes that have much stronger
Figure 4. Binding of purified b2GPI to cardiolipin. A) The binding
of b2GPI purified from human plasma to cardiolipin in the absence
(triangles) and in the presence (circles) of anti-b2GPI antibodies. B)
Inhibition of the binding of purified b2GPI to cardiolipin in the presence
of anti-b2GPI antibodies by the dimeric inhibitor A1-A1 (circles) and
monomeric inhibitor A1 (triangles). Fit to one-site binding and
inhibition models was performed on the raw data. The measured
OD405 values and the binding curves were normalized to the maximum
binding obtained from the fit. C) Comparison of the measured with
expected binding of b2GPI to cardiolipin calculated based on the fit of
the inhibition curves. Purified b2GPI bound to cardiolipin in the
presence of anti-b2GPI antibody without inhibitor (gray bar), with A1-
A1 (black bars) and with A1 (white bars). The OD405 values were
normalized to OD405 measured in the absence of inhibitor. The values of
measured relative binding and standard deviations (6SD) are indicated
above bar. The values of expected relative binding were calculated from
the fit of the titration data and are given in parenthesis.
doi:10.1371/journal.pone.0015345.g004
Figure 5. Inhibition of the binding of purified b2GPI to
cardiolipin by A1-A1 and A1 in the absence of anti-b2GPI
antibodies. The purified b2GPI bound to cardiolipin in the absence of
anti-b2GPI antibody with increasing amounts of A1-A1 (black bars) and
A1 (white bars). The OD405 values were normalized to OD405 measured
in the absence of inhibitor.
doi:10.1371/journal.pone.0015345.g005
Figure 6. Stereoview of the crystal structure of the isolated
domain V of b2GPI (b2GPI-DV). Backbone superposition of the
structures of b2GPI-DV chain A (green), chain B (blue) and the crystal
structure of domain V from the full-length b2GPI (PDB ID 1C1Z, residues
from 244 to 326) (red). The N- and C-termini, and a flexible loop in the
domain V are labeled. Figure was generated with the program PYMOL
[61]. The two molecules of b2GPI-DV in the asymmetric unit of the
crystal, chains A and B, have nearly identical structures with backbone
RMSD of 0.23 A ˚. Backbone superposition of domain V in the full-length
b2GPI onto the structure of b2GPI-DV have RMSD of 1.04 A ˚ and 0.97 A ˚
for chains A and B, respectively.
doi:10.1371/journal.pone.0015345.g006
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the monomeric b2GPI [44,52]. Because b2GPI/antibody com-
plexes expressing dimeric b2GPI have prothrombotic properties,
in contrast to monomeric pathologically inactive b2GPI, we
designed a dimeric inhibitor. We hypothesized that the dimeric
molecule A1-A1 preferentially targets multivalent pathological
b2GPI/anti-b2GPI antibody complexes leaving monomeric
b2GPI, which is abundant in plasma, practically unaffected. To
compare A1-A1 and A1 on the inhibition of the binding of b2GPI
to anionic phospholipids, we used different preparations of b2GPI,
such as b2GPI in normal human serum, b2GPI purified from
human plasma and recombinant domain V of b2GPI. b2GPI is a
flexible molecule that can adopt a circular [11] and extended
conformation [8,9,10]. b2GPI in plasma is predominantly in a
circular form [11] and the individual domain V closely resembles
domain V in the extended conformation of b2GPI, as we
demonstrated here by the X-ray crystallography.
We compared the binding curves for two preparations of b2GPI
and for b2GPI-DV in the absence and in the presence of the
dimerizing antibodies. In all three cases, we observed that the
presence of antibodies significantly enhanced the binding of
b2GPI and b2GPI-DV to cardiolipin, similarly to what was
previously detected for chimeric dimers of b2GPI compared to
b2GPI monomers [34]. The binding of b2GPI and b2GPI-DV to
cardiolipin-coated surface in the presence of constant amounts of
dimerizing antibodies increases with the addition of b2GPI or
b2GPI-DV reaching saturation when all antibodies are engaged in
complexes. For the inhibition studies, we used concentrations of
b2GPI and b2GPI-DV in the linear region of the binding curves at
about 50-60% of the maximal binding. Comparison of the binding
curves in the presence and in the absence of antibodies suggests
that the contribution of b2GPI or b2GPI-DV monomers to total
binding in the presence of antibodies is negligible compared to the
contribution of b2GPI/antibody or b2GPI-DV/antibody com-
plexes and, therefore, the inhibition curves measured in the
presence of antibodies describe the inhibition of a fraction of
dimerized molecules.
We determined that, regardless of the source of b2GPI, 1) A1-
A1 is much more efficient in inhibition of the binding of b2GPI/
antibody complexes to anionic phospholipids than A1 and 2) the
Table 1. Crystallographic statistics.
Data Statistics
Beamline NSLS X29
Wavelength (A ˚) 1.075
Space group P1
Cell parameters (A ˚) a=24.29 b=38.09 c=49.51
(u) a=93.83 b=102.65 c=90.09
Resolution range (A ˚)
a 38.0–1.9 (2.0–1.9)
Total number of observations
a 48247 (7052)
Total number of unique
a 12817 (1850)
Completeness (%)
a 94.3 (93.8)
I/I(s)
a 12.6 (4.5)
Multiplicity
a 3.8 (3.8)
Rmerge (%)
a 6.1 (26.7)
Molecules in asymmetric unit 2
Refinement Statistics
Free reflections (%) 5
Rwork (%) 18
Rfree (%) 21.8
Protein atoms including H 2812
Waters 110
RMSD from Ideal Geometry
Bond angles (u)1 . 5
Bond lengths (A ˚) 0.015
Chirality 0.102
Planarity 0.007
Dihedral 13.4
Ramachandran Plot
number of residues in:
Preferred regions 159 (96.95%)
Allowed regions 5 (3.05%)
Disallowed regions 0
aValues in parenthesis correspond to the highest resolution shell.
doi:10.1371/journal.pone.0015345.t001
Figure 7. Binding of the individual domain V of b2GPI (b2GPI-
DV) to cardiolipin. A) The binding of b2GPI-DV to cardiolipin in the
absence (triangles) and in the presence (circles) of the dimerization
antibodies. B) Inhibition of the binding of b2GPI-DV to cardiolipin in the
presence of dimerization antibodies by the dimeric inhibitor A1-A1
(circles) and monomeric inhibitor A1 (triangles). Fit to one-site binding
and inhibition models was performed on the raw data. The measured
OD405 values and the binding and inhibition curves were normalized to
the maximum binding obtained from the fit.
doi:10.1371/journal.pone.0015345.g007
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phospholipids by either A1-A1 or A1 is practically identical and
weak. We also observed that the inhibition of both b2GPI in
serum and the individual domain V by A1 is identical in the
absence of dimerization antibodies, suggesting that A1 binds the
circular and extended forms of b2GPI with the same affinity.
Therefore, the binding site for A1 is not obscured on the circular
form of b2GPI. Anti-b2GPI antibodies in patients with antiphos-
pholipid syndrome are heterogeneous and their epitopes are
scattered over domains I to IV of b2GPI [51,53]. Some antibodies
in patients with antiphospholipid syndrome might bind circular
b2GPI and some antibodies might need an extended b2GPI to
have their epitopes exposed. Our results demonstrated that when
b2GPI, whether circular or extended, is dimerized by anti-b2GPI
antibodies, it is more strongly inhibited by A1-A1 than by
monomeric A1 by forming stable b2GPI/anti-b2GPI/A1-A1
complexes (Figure 10). We measured in vitro the serum stability
of A1-A1. About 35% of A1-A1 remained intact after incubation
in serum at 37uC for more than two weeks, indicating that A1-A1
might have favorable pharmacokinetic properties. Given that A1
modules are naturally expressed, the A1-A1 inhibitor is unlikely to
be immunogenic.
In our previous work, we have shown that LA modules from
different lipoprotein receptors bind to the same site on b2GPI-DV
[46]. Therefore, A1-A1 inhibits the binding of b2GPI/antibody
complexes not only to ApoER2, but to other lipoprotein receptors
as well. Whether other lipoprotein receptors besides ApoER2
contribute to the pathology of antiphospholipid syndrome awaits
further investigation. Our results suggest that A1-A1 may be a
starting point in the development of the effective inhibitor that
interferes with the binding of b2GPI/antibody complexes to
anionic phospholipids and lipoprotein receptors. The binding
affinity of A1-A1 for b2GPI/anti-b2GPI antibody complexes can
be improved in two ways: by optimization of the linker between
the two A1 modules and by improving the binding affinity of A1
for b2GPI-DV. Eventually, the A1-based inhibitor can be replaced
with small molecule compounds in a dimerized form.
We believe the approach of using a dimeric inhibitor that blocks
b2GPI in the pathological multivalent b2GPI/anti-b2GPI com-
plexes holds significant promise. In these studies, we are inhibiting
a well characterized binding site for lipoprotein receptors on
b2GPI, instead of preventing the binding of antibodies to b2GPI,
which are highly heterogeneous in APS patients. Our approach to
target the dimerized b2GPI with a dimeric inhibitor could be
applied to other pathologically important interactions of b2GPI/
antibody complexes. As soon as the binding sites on b2GPI for
other APS-related receptors are mapped and characterized in
detail, they can be targeted by dimeric inhibitors.
In conclusion, we developed and tested a novel dimeric
inhibitor of the b2GPI/antibody complexes. This dimeric
inhibitor preferentially targets b2GPI dimerized by anti-b2GPI
antibodies compared to pathologically inactive monomeric b2GPI.
It prevents the binding of b2GPI/antibody complexes to anionic
phospholipids and ApoER2, and might eventually lead to a drug
specific for antiphospholipid syndrome.
Materials and Methods
Protein expression and purification
Monomeric A1 is a fragment of mouse ApoER2 (residues 12–47
from the mature protein). The dimeric inhibitor, A1-A1, was
constructed to contain two A1 fragments connected by a Gly-Ser-
Ser-Gly linker. A1 and A1-A1 containing an extra N-terminal Ala
and C-terminal Glu-Ala residues were expressed in E.coli as
TrpLE fusion proteins and purified from inclusion bodies
essentially as previously described [54]. Domain V of b2GPI
(residues 244–326), was subcloned into a pET15b vector
Figure 8. Comparison of the inhibition of b2GPI in serum with
the inhibition of the isolated domain V by monomeric A1 in the
absence of dimerization antibodies. Inhibition of the binding of
b2GPI-DV by A1 (circles); inhibition of the binding of b2GPI in serum by
A1 (triangles).
doi:10.1371/journal.pone.0015345.g008
Figure 9. Stability of the A1-A1 inhibitor in human serum at 376C. HPLC chromatograms of A1-A1 incubated in human serum for
the amount of time indicated on each panel. Elution of the A1-A1 inhibitor was monitored with a linear gradient of 0.1% per minute of
acetonitrile with 0.1% TFA. The gradient started at 15 minutes from about 26% of acetonitrile/TFA.
doi:10.1371/journal.pone.0015345.g009
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followed by the sequence recognized by the Tobacco Etch Virus
(TEV) protease so that the tag can be removed. To make the
domain V of b2GPI recognized by antibodies directed to an HA
peptide, the HA sequence, YPYDVPDYA, was introduced at the
N-terminus of domain V right after the TEV cleavage site.
Domain V with and without the peptide tag was expressed in
E.coli, recovered from inclusion bodies, cleaved with TEV and
refolded by dialysis at 4uC under conditions permitting disulfide
exchange before final purification by reversed-phase HPLC on a
C18 column. Protein concentrations were calculated from the
measured absorbance of samples at 280 nm using extinction
coefficients from the output of ExPASy Protparam tool (http://
expasy.org/tools/protparam.html). A full-length b2GPI was
purchased from Haematologic Technologies, Inc. Concentrations
of b2GPI were calculated using an extinction coefficient at
280 nm E
1% of 10 and molecular weight of 54200, as suggested by
the supplier.
Crystallization, data collection and structure
determination of b2GPI-DV
Initial crystallization condition was determined in crystallization
screen performed at the Hauptman-Woodward Medical Research
Institute [55]. The best crystal of b2GPI-DV was obtained at room
temperature in hanging drop by combining 1 mLo fb2GPI-DV
(7 mg/ml in 20 mM HEPES, pH 7.0) with 1 mL of reservoir
solution containing 100 mM ammonium sulfate, 40% PEG 1500,
100 mM bis-Tris, pH 7.2. The reservoir solution supplemented
with 20% glycerol was used as cryoprotectant. Data was collected
from a single crystal at beamline X29A of Brookhaven National
Laboratories (NSLS). The crystals belong to the space group P1
with two molecules of b2GPI-DV per asymmetric unit and a
solvent content of 45%. Data was processed with MOSFLM [56].
A total of 5% of reflections were excluded and used for Rfree
calculations. The structure was solved by molecular replacement
with PHASER [57] using coordinates of domain V extracted from
the crystal structure of b2GPI (PDB ID 1C1Z). The initial model
determined by PHASER was adjusted with the program COOT
[58] and refined using the program REFMAC5 [59]. The final
refinement was performed with PHENIX software suit [60].
Assay for the binding and inhibition of the binding of
b2GPI and b2GPI-DV to a cardiolipin-coated surface
Cardiolipin-coated 96 well plates from the ImmunoWELL
cardiolipin IgG test kit (GenBio) were blocked with 0.5% of skim
milk and 2% BSA in 20 mM Tris, 100 mM NaCl, 2 mM CaCl2,
pH 7.4. The assay buffer contained 20 mM Tris, 100 mM NaCl,
2 mM CaCl2, pH 7.4 with 2% BSA and the wash buffer was
20 mM Tris, 100 mM NaCl, 2 mM CaCl2, pH 7.4. When the
purified b2GPI (Haematologic Technologies, Inc.) was used in
experiments, 27 mM glycine was added to the assay buffer to
account for glycine present in the stock solution of b2GPI. b2GPI
bound to cardiolipin was detected with peroxidase-conjugated
anti-b2GPI antibodies (Cedarlane, CL20021HP, 2 mg/ml) diluted
1:2500. To detect b2GPI-DV bound to cardiolipin, we used
peroxidase-conjugated anti-HA antibody (Abcam, ab1265, 1 mg/
ml) directed to HA epitope tag at the N-terminus of b2GPI-DV
diluted 1:2500. The peroxidase activity of the bound antibodies
was detected using 2-29-azino-di-[3-ethylbenzthizzoline] sulfonate
(ABTS) chromogenic reagent by measuring OD at 405 nm. All
measurements were done in triplicates and corrected to blank
before data fitting. The blank contained all components except for
b2GPI, serum or b2GPI-DV. The binding and inhibition data was
fitted to one-site models using the nonlinear least-squares
Marquardt-Levenberg algorithm implemented in GNUPLOT
program. The fits of the raw data and the titration data points
were then normalized to the maximum binding determined from
the fit to facilitate comparison.
For the binding studies, 50 ml of increasing concentrations of
either b2GPI (Haematologic Technologies, Inc.), pooled normal
human serum (Innovative Research) or the purified recombinant
b2GPI-DV were applied to wells and incubated for 1 hour at
room temperature. After washing, anti-b2GPI or anti-HA
antibody was added to wells and incubated for 1 hour at room
temperature before detection. In the second set of experiments,
samples containing various concentrations of b2GPI, pooled
normal human serum or b2GPI-DV were first incubated for
1 hour at room temperature with the anti-b2GPI or anti-HA
antibodies. Then, the samples were applied to cardiolipin,
incubated for 1 hour, washed, and bound b2GPI or b2GPI-DV
was detected.
Figure 10. Complex formation between b2GPI, inhibitor and anti-b2GPI antibody. The binding of A1-A1, but not monomeric A1, forms
stable b2GPI/anti-b2GPI/A1-A1 complex regardless of localization of the epitope for anti-b2GPI antibody and whether circular or extended b2GPI is
dimerized by antibody. b2GPI (blue), A1 or A1-A1 inhibitor (red) and anti-b2GPI antibody (green).
doi:10.1371/journal.pone.0015345.g010
Dimeric Inhibitor of B2GPI/Anti-B2GPI Complexes
PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e15345For the inhibition studies, increasing concentrations of A1 or
A1-A1 were added to a constant amount of b2GPI (50 nM),
normal human serum (1%) or b2GPI-DV (130 nM) and incubated
for 1 hour at room temperature. Then, 50 ml of the mixtures were
incubated on wells for the additional 1 hour. After washing, 50 ml
of either anti-b2GPI or anti-HA antibody was added to wells and
incubated for 1 hour before detection. In the second set of
experiments, 50 ml of samples containing increasing concentra-
tions of A1 or A1-A1 and the constant amounts of either b2GPI
(10 nM), normal human serum (0.04%) or b2GPI-DV (30 nM)
were first incubated for 1 hour at room temperature with the anti-
b2GPI or anti-HA antibodies. Then, samples were incubated on
wells for an additional 1 hour and, after washing, the bound
b2GPI/anti-b2GPI or b2GPI-DV/anti-tag antibody complexes
were detected.
Measurements of the stability of A1-A1 in serum
Lyophilized A1-A1 purified by reversed-phase chromatography
was dissolved in water and its concentration measured by
absorbance at 280 nm. The required amount of A1-A1 (180 mg)
was then lyophilized and, subsequently, dissolved in 360 mlo f
pooled normal human serum (Innovative Research). Serum with
A1-A1 was filtered through a 0.2 mm eppendorf centrifuge filter,
divided into 40 ml samples and set for incubation at 37uC. At
timed intervals, 900 ml of 10% acetonitrile with 0.1% TFA in
water (buffer A) was added to a 40 ml sample of A1-A1 in serum.
Filtered samples were analyzed by reversed-phase HPLC on a C18
column using a linear gradient of 0.1% per minute of buffer B
(acetonitrile with 0.1% TFA) staring at 15 minutes from 26% of
acetonitrile and monitored for 30 minutes.
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